Trials / Completed
CompletedNCT00048620
Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
Double-Blind,2 Dose Group Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- BioMarin Pharmaceutical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N-acetylgalactosamine 4-sulfatase |
Timeline
- Start date
- 2000-09-01
- Completion
- 2005-11-01
- First posted
- 2002-11-06
- Last updated
- 2006-11-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00048620. Inclusion in this directory is not an endorsement.